{"id":387611,"date":"2020-11-24T08:20:22","date_gmt":"2020-11-24T13:20:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387611"},"modified":"2020-11-24T08:20:22","modified_gmt":"2020-11-24T13:20:22","slug":"investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/","title":{"rendered":"InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LOS ANGELES, Nov.  24, 2020  (GLOBE NEWSWIRE) &#8212; via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7v3MRcIJ3A_VMx0YmqJZb6gzviglZOJSlo13FF2oaW1HCPTg_Be9iRL7t5sO-wrgDh0V0AAGbpBTT_2dhwXNQQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorWire<\/a> \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7v3MRcIJ3A_VMx0YmqJZb1dDmcrubgiPxYX-2GA83H6eguSCQJ8KNwzyLmuGvbRXQzEUCLBnY0wfqqK5e3fkhtlhepHGDKZb-oYYGs4Gmbk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorBrandNetwork<\/a>\u00a0(\u201cIBN\u201d), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of\u00a0the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MuAW8FuUKQ68ln_A8bMmHv7m6V6-jy8p06wWQTCoUGYjkVF6qkSEYfpKSM1PGhljzlhEp-y-USLqcInmU-ZNAg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Stock2Me Podcast<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O2tJYzWQfO9zwvksn6D4AMZOWes1QaOYLPYDBOT6P_C2F7zYmqY8Rsio07NI9diY\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">\u00a0<\/a>as part of its sustained effort to provide specialized content distribution via widespread syndication channels.<\/p>\n<p align=\"justify\">Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets.<\/p>\n<p align=\"justify\">Stock2Me\u2019s latest podcast features James Sapirstein, president &amp; CEO of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h4BlN_aKqPUnmq75TlIXcXIQUniT87mrcmPUDzKh7HUxwgfdQLPG14XIUGh7W0oCsws7LMfp2XIvJFMNaoWzrc8tmh9FOdi6Zj3VZH19m25PnPeRU3fxzNUNKn_6TNDb-2jMRHtrnFyx3DQQ1kGywIfp5qk2z0W6ltSyqZ5-ZDY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">AzurRx BioPharma Inc. (NASDAQ: AZRX)<\/a>.<\/p>\n<p align=\"justify\">\u201cAzurRx Bio has been around for five years. \u2026 Our main product, MS1819, is being studied in chronic pancreatitis and in the GI effects of cystic fibrosis,\u201d Sapirstein stated in the interview. \u201cThe market for this particular product (in chronic pancreatitis, competing against pancreatic enzyme replacement therapy (PERT) is about $1 billion outside of the United States and several hundred million dollars inside the United States. The other market is cystic fibrosis. It\u2019s over a $2 billion market worldwide for PERT.\u201d<\/p>\n<p align=\"justify\">AzurRx currently has two ongoing clinical trials for MS1819. The first is a Phase 2 Cystic Fibrosis Combination Trial examining MS1819 in combination with PERT, which is expected to produce topline data in Q2 2021.<\/p>\n<p align=\"justify\">The company\u2019s second ongoing trial is a Phase 2b Cystic Fibrosis Option 2 monotherapy trial that is expected to produce topline data in Q1 2021. Describing this study, Sapirstein noted, \u201cThis is a crossover design study. We place patients on PERT, the existing standard of care therapy, and we also put another line of patients on our drug. These patients take the drugs for three weeks, then we crossover. These patients are not being studied versus placebo. \u2026 We\u2019re actually adding another arm where we can dose escalate, because we enrolled the trial very quickly despite COVID. \u2026 Because of that, we decided to get some more data out of this trial with <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t89xNftyurvSpd6rY2nC1WcVa9WMk9d2lmvNbtIAgQ2xMr_Cgf7Zky6CUc5kmw_uf-Z1nHLNvW_BXDsAMtWRdSa_7yd3IfhytfJNGXmIAJmZaonXCiLUftzwus-9YMHB8fug2JF2Ar2232KQz5XFbO0g9NJTskG2EhMeiJzG-v0Wr3ns-HguOZ4jr-RucV-3lKC02TY1Wyog3PSUPzrEsNQwxw7Ebp5yIlFNEFHpi5Q=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">another arm<\/a>.\u201d<\/p>\n<p align=\"justify\">Sapirstein went on to discuss the impacts of COVID-19 on AzurRx. The company made a number of adjustments to its clinical development strategy in an effort to better navigate the pandemic. \u201cI immediately, back in February, told my clinical group that this virus is going to be pretty bad and a lot of countries are going to start shutting down. For our combination trial, we decided to start getting some backups. We called the folks in Europe that were working on our trial and told them to get as many patients as possible,\u201d he said. \u201cWe also opened up Poland and Turkey. \u2026 It takes several months to get these sites up and running and calibrated, so, on the combination trial, we lost about a month on COVID, but not a significant amount of time.\u201d<\/p>\n<p align=\"justify\">\u201cIn the United States, we took a very different approach with our Option 2 trial,\u201d Sapirstein continued. \u201cBecause these patients don\u2019t need a lot of bloodwork, we decided to sequester these folks in hotels. Obviously, there was a lot of hotel space available. We put that into our protocol; we got it approved by the FDA. \u2026 That\u2019s how we were able to do it this quickly.\u201d<\/p>\n<p align=\"justify\">Join InvestorBrandNetwork\u2019s Stuart Smith and AzurRx\u2019s James Sapirstein in exploring how AzurRx is working to redefine the standard of care for patients living with cystic fibrosis and chronic pancreatitis.<\/p>\n<p align=\"justify\">To catch the entire episode and subscribe for future episodes please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bMQ9A20IG58Wh65dRvhRfMnw2LpDnbEEfFbt16qCPRgMTFGHecDmWy1vThPiNrIi3_YeO-N4QIBP2mcUUjGPCMnOmRPPv6yS-bDz95C4w_Q=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/podcast.stock2me.com<\/a><\/p>\n<p align=\"justify\">The latest installment of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P29m_FN7gQit6iCwP66iQr6ZUS7pEJX4KS3ZYQwBEks2p2Ev3_GZT0E_tjk4HQpZ5tC3p6p124AYdk2t8q8b_Oae2wBamPlSwvszPm7gCxU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">The Stock2Me Podcast<\/a> continues to\u00a0reinforce InvestorBrandNetwork\u2019s commitment to the expansion of its robust network of brands, client partners, followers and the growing\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EbXjMChNdb9Krir0XCbqbvJjBkxiU4CoguvZ5HVeBMxoXXD3MF9EDqi--keb24GRr9ZJuqZYZRdCVZeETZ_qNB9sBu_lJEv5lIuYYDC4fZphGihuXLs8bqg1KjeV6TbHKSWqorSQv9Stq0uTlUCguiNUkh4CX8RTGNu3a5xYD-k=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">IBN Podcast Series<\/a>. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M_tu5qQlQvkbtCRGHrdrA891JtrVDhTHT5vZsgRUK5jgSI-J6oMnrmYYt0erFGh_4ExYAFc6rZLPeXfLGSUpTRMvA04ksTAHuIx1BgRwWLkZfHfphIfz-grTNIXp1pld09a5cTiKA8QvYyyLqsUbng==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">500+ public and private companies<\/a>.<\/p>\n<p>To learn more about IBN\u2019s achievements and milestones via a visual timeline visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bMQ9A20IG58Wh65dRvhRfJr9JLxCE6--qeEmK3ShAB6SBcKjWqAg207BKa_J0Xmpqcim8Tp8f8mSLX29nyScRY_hUplDUr4Xqnh2oaQFB4o=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/IBN.fm\/TimeLine<\/a><\/p>\n<p align=\"justify\">\n        <strong>About InvestorBrandNetwork<\/strong>\n      <\/p>\n<p align=\"justify\">The\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7v3MRcIJ3A_VMx0YmqJZb-Ci0oa_2ozCuEkMxJSP-ZDhde414iNtSnLzLJ-jPIwsmFPNdIxEmhnMmgIgBLubAv63bLsxhFxZ6K2ilxY4ZihqkFQ9WisCOGm1Ko1VJ_QB\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorBrandNetwork<\/a>\u00a0(\u201cIBN\u201d) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.<\/p>\n<p align=\"justify\">Through\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=i-QEiAnRcBy_yChrv9QspXhSykheksQhBKA3i1NV35LieFCwv91R_Eot_MXuwTFQ5BuYDpc44i9CTgQBb7ZqQEvFxsZXulcZVHZZxySL_VM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">NetworkNewsWire<\/a>\u00a0(\u201cNNW\u201d) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7v3MRcIJ3A_VMx0YmqJZb7UyANQR4OqgU1MI9fTqryslB31CZ9StO8a-ucIYQIqhP6WfktW0FXe4wOtv2ECsbVwzav3lpdHJdevM5n8RFcw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorWire<\/a>\u00a0to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.<\/p>\n<p align=\"justify\">For more information on IBN, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bMQ9A20IG58Wh65dRvhRfGV34NhjKi1BlG-FQ7fswE-qNTGEZPKDi-ZZ_1IejMlHzE3DMorkpXQwmim5UpjbRmUZlt4FNIU9fRwVn3uQg0-vgW_ccozN32aTZyeSXABQAq6tp1iG60uLgreiwGVeZA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.InvestorBrandNetwork.com<\/a>.<\/p>\n<p align=\"justify\">Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN, wherever published or re-published:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bMQ9A20IG58Wh65dRvhRfBdZqSae5Y8SLG5TiAK82drRipGOes0jqp0ZaO2r_e6V8dme9MVd92G9sYKnkCtqFu4iHLivLLCkX2mBQDTHim4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/IBN.fm\/Disclaimer<\/a><\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company&#8217;s SEC filings. These risks and uncertainties could cause the company&#8217;s actual results to differ materially from those indicated in the forward-looking statements.<\/p>\n<p align=\"justify\">\n        <strong>Corporate Communications<\/strong>\n      <\/p>\n<p>InvestorBrandNetwork (IBN)<br \/>Los Angeles, California<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pKrCjXIuMBjnX3oJVog_n9w5o0USn4V-yfq3qteg59oPG7bpsRddisEe-j2hghQnhGZ2ghtMA39om2NoTU3chjnV5iMyV31HONSaNYkxq6vzlgQCeSDefR8uyffAhmlA\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.InvestorBrandNetwork.com<\/a><br \/>310.299.1717 Office<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sagcIKSJsEAZCkY_1gd_I6kb1ijitB8Lrc3ncF7IaZCe9ZnXk4k5Wp8Th1karptyc9-PUX3MupzFACkgR7AOjwCtJETyoqnyYUCTbp0dW_OqyGmUGViw5ehZ-o_kSAsD\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Editor@InvestorBrandNetwork.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDAwNyMzODM3OTA2IzIwODg3OTk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/3f08bda9-7a6d-460e-b987-a6a4fe8e8408\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2013 InvestorBrandNetwork\u00a0(\u201cIBN\u201d), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of\u00a0the Stock2Me Podcast\u00a0as part of its sustained effort to provide specialized content distribution via widespread syndication channels. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me\u2019s latest podcast features James Sapirstein, president &amp; CEO of AzurRx BioPharma Inc. (NASDAQ: AZRX). \u201cAzurRx Bio has been around for five years. \u2026 Our main product, MS1819, is being studied in chronic pancreatitis and in the GI effects of cystic fibrosis,\u201d Sapirstein stated in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387611","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2013 InvestorBrandNetwork\u00a0(\u201cIBN\u201d), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of\u00a0the Stock2Me Podcast\u00a0as part of its sustained effort to provide specialized content distribution via widespread syndication channels. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me\u2019s latest podcast features James Sapirstein, president &amp; CEO of AzurRx BioPharma Inc. (NASDAQ: AZRX). \u201cAzurRx Bio has been around for five years. \u2026 Our main product, MS1819, is being studied in chronic pancreatitis and in the GI effects of cystic fibrosis,\u201d Sapirstein stated in &hellip; Continue reading &quot;InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T13:20:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDAwNyMzODM3OTA2IzIwODg3OTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein\",\"datePublished\":\"2020-11-24T13:20:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/\"},\"wordCount\":980,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDAwNyMzODM3OTA2IzIwODg3OTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/\",\"name\":\"InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDAwNyMzODM3OTA2IzIwODg3OTk=\",\"datePublished\":\"2020-11-24T13:20:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDAwNyMzODM3OTA2IzIwODg3OTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDAwNyMzODM3OTA2IzIwODg3OTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/","og_locale":"en_US","og_type":"article","og_title":"InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein - Market Newsdesk","og_description":"LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2013 InvestorBrandNetwork\u00a0(\u201cIBN\u201d), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of\u00a0the Stock2Me Podcast\u00a0as part of its sustained effort to provide specialized content distribution via widespread syndication channels. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me\u2019s latest podcast features James Sapirstein, president &amp; CEO of AzurRx BioPharma Inc. (NASDAQ: AZRX). \u201cAzurRx Bio has been around for five years. \u2026 Our main product, MS1819, is being studied in chronic pancreatitis and in the GI effects of cystic fibrosis,\u201d Sapirstein stated in &hellip; Continue reading \"InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T13:20:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDAwNyMzODM3OTA2IzIwODg3OTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein","datePublished":"2020-11-24T13:20:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/"},"wordCount":980,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDAwNyMzODM3OTA2IzIwODg3OTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/","name":"InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDAwNyMzODM3OTA2IzIwODg3OTk=","datePublished":"2020-11-24T13:20:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDAwNyMzODM3OTA2IzIwODg3OTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDAwNyMzODM3OTA2IzIwODg3OTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-stock2me-podcast-featuring-azurrx-biopharma-inc-president-ceo-james-sapirstein\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President &amp; CEO James Sapirstein"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387611"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387611\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}